Resveratrol ： Atherosclerosis
C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。Improves FMD and reduces inflammatory markers. RESVACE trial was negative for cardiac function in heart failure. Bioavailability challenges limit clinical translation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'heartcited.com';
const params = 'ingredient\u003Dresveratrol\u0026condition\u003Datherosclerosis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
結論
Improves FMD and reduces inflammatory markers. RESVACE trial was negative for cardiac function in heart failure. Bioavailability challenges limit clinical translation.
Key Study Findings
Review
Dietary Antioxidants, Polyphenols, and Vascular Health: Insights From Ultrasound Measurement of Carotid Intima-Media Thickness and …
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: older adults and individuals with neurodegenerative disorders
Review
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: review of age-related cardiac dysfunction and heart failure mechanisms
Review
Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Review of anti-atherosclerotic supplements and bleeding
Review
Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects.
Dose: None
vs: None
Outcome: TGF/ERK pathway inhibition and AS improvement
効果: None
None
対象集団: Atherosclerosis populations
In Vitro
Genome-Wide Transcriptional Profiling Reveals PHACTR1 as a Novel Molecular Target of Resveratrol in Endothelial Homeostasis.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: None
Other
Supplementation with Resveratrol, Piperine and Alpha-Tocopherol Decreases Chronic Inflammation in a Cluster of Older Adults …
Dose: None
vs: Conventional treatment
Outcome: effect of a dietary supplement on chronic inflammation …
効果: None
p < 0.05
対象集団: None
Key Statistics
5
研究数
400
参加者数
↑
Positive
C
グレード
Referenced Papers
Phytotherapy research : …
2026
ESC heart failure
2025
58 件の引用
International journal of …
2025
1 件の引用
Biomedicine & pharmacotherapy …
2022
34 件の引用
Nutrients
2022
2 件の引用
Nutrients
2020
16 件の引用
Pharmacological research
2019
31 件の引用
Nutrients
2018
77 件の引用
Oxidative medicine and …
2017
87 件の引用
Pharmacological research
2017
63 件の引用
Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals.
Review
Nutrition reviews
2011
97 件の引用
Journal of cardiovascular …
2009
297 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 150-500 mg/day
- cardiovascularsupport:
- 250-500 mg/day trans-resveratrol
上限量： Not formally established; GI discomfort common above 1,000 mg/day
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Neutral | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
推奨摂取タイミング： With meals; bioavailability enhanced by piperine co-supplementation
Safety & Side Effects
報告されている副作用
- ⚠ Gastrointestinal discomfort (nausea, diarrhea, cramping) at high doses
- ⚠ Headache
- ⚠ May have estrogenic activity at high doses
既知の相互作用
- ● Anticoagulants (may inhibit platelet aggregation)
- ● CYP450 substrates (may inhibit CYP1A2, CYP3A4, CYP2D6)
- ● Blood pressure medications (additive hypotensive effect)
- ● Estrogen-sensitive conditions (weak estrogenic activity)
耐容上限摂取量： Not formally established; GI discomfort common above 1,000 mg/day
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Resveratrol help with Atherosclerosis?
Based on 5 studies with 400 participants, there is limited but promising evidence that Resveratrol may support Atherosclerosis management. Our evidence grade is C (Some Evidence).
How much Resveratrol should I take for Atherosclerosis?
Studies have used various dosages. A commonly studied range is 150-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Resveratrol?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea, cramping) at high doses, Headache, May have estrogenic activity at high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Resveratrol and Atherosclerosis?
We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Atherosclerosis
Resveratrol 他の症状・状態について
References
- [1] Lei Wang et al.. Phytother Res. 2026. Dietary Antioxidants, Polyphenols, and Vascular Health: Insights From Ultrasound Measurement of Carotid Intima-Media Thickness and Their Association With Cognitive Function … doi:10.1002/ptr.70198 PubMed
- [2] Zhuyubing Fang et al.. ESC Heart Fail. 2025. Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues. doi:10.1002/ehf2.14947 PubMed
- [3] Maria-Zinaida Dobre et al.. Int J Mol Sci. 2025. Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks. doi:10.3390/ijms262010183 PubMed
- [4] Shitian Guo et al.. Biomed Pharmacother. 2022. Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects. doi:10.1016/j.biopha.2022.113775 PubMed
- [5] Meiming Su et al.. Nutrients. 2022. Genome-Wide Transcriptional Profiling Reveals PHACTR1 as a Novel Molecular Target of Resveratrol in Endothelial Homeostasis. doi:10.3390/nu14214518 PubMed
- [6] Raúl Francisco Pastor et al.. Nutrients. 2020. Supplementation with Resveratrol, Piperine and Alpha-Tocopherol Decreases Chronic Inflammation in a Cluster of Older Adults with Metabolic Syndrome. doi:10.3390/nu12103149 PubMed
- [7] Wang Anlu et al.. Pharmacol Res. 2019. Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. doi:10.1016/j.phrs.2019.02.018 PubMed
- [8] Michał Wiciński et al.. Nutrients. 2018. Beneficial Effects of Resveratrol Administration-Focus on Potential Biochemical Mechanisms in Cardiovascular Conditions. doi:10.3390/nu10111813 PubMed
- [9] A Tressera-Rimbau et al.. Oxid Med Cell Longev. 2017. Dietary Polyphenols in the Prevention of Stroke. doi:10.1155/2017/7467962 PubMed
- [10] Enrico Gugliandolo et al.. Pharmacol Res. 2017. Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury. doi:10.1016/j.phrs.2017.06.014 PubMed
- [11] Ling Zhao et al.. Nutr Rev. 2011. Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals. doi:10.1111/j.1753-4887.2011.00394.x PubMed
- [12] Alberto A A Bertelli et al.. J Cardiovasc Pharmacol. 2009. Grapes, wines, resveratrol, and heart health. doi:10.1097/FJC.0b013e3181bfaff3 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。